Revised: September 11, 2013
Accepted: December 12, 2013
Published online: January 26, 2014
Processing time: 207 Days and 16.5 Hours
AIM: To investigate the impact of primary reperfusion therapy (RT) on early and late mortality in acute right ventricular infarction (RVI).
METHODS: RVI patients (n = 679) were prospectively classified as without right ventricular failure (RVF) (class A, n = 425, 64%), with RVF (class B, n = 158, 24%) or with cardiogenic shock (CS) (class C, n = 96, 12%). Of the 679 patients, 148 (21.7%) were considered to be eligible for thrombolytic therapy (TT) and 351 (51.6%) for primary percutaneous coronary intervention (PPCI). TIMI 3-flow by TT was achieved for A, B and C RVI class in 65%, 64% and 0%, respectively and with PPCI in 93%, 91% and 87%, respectively.
RESULTS: For class A without RT, the mortality rate was 7.9%, with TT was reduced to 4.4% (P < 0.01) and with PPCI to 3.2% (P < 0.01). Considering TT vs PPCI, PPCI was superior (P < 0.05). For class B without RT the mortality was 27%, decreased to 13% with TT (P < 0.01) and to 8.3% with PPCI (P < 0.01). In a TT and PPCI comparison, PPCI was superior (P < 0.01). For class C without RT the in-hospital mortality was 80%, with TT was 100% and with PPCI, the rate decreased to 44% (P < 0.01). At 8 years, the mortality rate without RT for class A was 32%, for class B was 48% and for class C was 85%. When PPCI was successful, the long-term mortality was lower than previously reported for the 3 RVI classes (A: 21%, B: 38%, C: 70%; P < 0.001).
CONCLUSION: PPCI is superior to TT and reduces short/long-term mortality for all RVI categories. RVI CS patients should be encouraged to undergo PPCI at a specialized center.
Core tip: It is, up to our knowledge the largest series of acute right ventricular infarction (RVI) patients where all the clinical RVI spectrum is considered. RVI is analyzed in relation to primary reperfusion procedures, over a study period with a more widespread use of primary percutaneous coronary intervention (PPCI) together with the advent of stents and antiplatelet agents to provide a better insight into reperfusion trends and results in acute RVI. According to our findings, in all RVI hemodynamic scenario PPCI is superior to thrombolytic therapy (TT) and reduces short and long-term mortality for all 3 RVI categories. Patients in cardiogenic shock should be encouraged to undergo PPCI rather than TT at a specialized center.